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Abstract
Bone marrow stromal cells regulate marrow haematopoiesis by secreting growth factors such as macrophage colony
stimulating factor (M-CSF) that regulates the proliferation, differentiation and several functions of cells of the mononuclear-
phagocytic lineage. By using a specific ELISA we found that their constitutive secretion of M-CSF is enhanced by tumour
necrosis factor-K (TNF-K). The lipid mediator prostaglandin E2 (PGE2) markedly reduces in a time- and dose-dependent
manner the constitutive and TNF-K-induced M-CSF synthesis by bone marrow stromal cells. In contrast, other lipid
mediators such as 12-HETE, 15-HETE, leukotriene B4, leukotriene C4 and lipoxin A4 have no effect. EP2/EP4 selective
agonists (11-deoxy PGE1 and 1-OH PGE1) and EP2 agonist (19-OH PGE2) inhibit M-CSF synthesis by bone marrow
stromal cells while an EP1/EP3 agonist (sulprostone) has no effect. Stimulation with PGE2 induces an increase of intracellular
cAMP levels in bone marrow stromal cells. cAMP elevating agents (forskolin and cholera toxin) mimic the PGE2-induced
inhibition of M-CSF production. In conclusion, PGE2 is a potent regulator of M-CSF production by human bone marrow
stromal cells, its effects being mediated via cAMP and PGE receptor EP2/EP4 subtypes. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Macrophage colony stimulating factor (M-CSF) is
a key regulator of the proliferation, di¡erentiation
and of several functions of cells of the mononu-
clear-phagocytic lineage [1,2]. M-CSF can act di-
rectly on haematopoiesis by promoting, in combina-
tion with interleukin (IL)-3 or IL-6, the growth of
monocyte/macrophage colonies from human blood
CD34 progenitor cells [3,4]. M-CSF can act indi-
rectly on haematopoiesis by stimulating the macro-
phagic production of numerous cytokines that, in
turn, act positively or negatively on haematopoiesis
[1,2].
Human bone marrow stromal cells regulate hae-
matopoiesis by secreting cytokines and CSFs [5,6].
Bone marrow stromal cells produce M-CSF consti-
tutively and increase their production in response to
proin£ammatory molecules such as interleukin-1
(IL-1) and platelet-activating factor (PAF) [7,8].
Conversely, no result is available concerning mole-
cules that down-regulate their M-CSF synthesis.
Among lipid mediators, the arachidonic acid (AA)
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metabolite prostaglandin E2 (PGE2) reduces the se-
cretion of CSFs (including M-CSF) by human mono-
cytes and synovial ¢broblasts [9,10]. PGE2 acts
through membrane receptors. Four di¡erent genes
coding for PGE2 receptors (EP receptors) are cloned
and named as EP1, EP2, EP3 and EP4 based on the
relative agonist or antagonist potencies of a number
of di¡erent analogues of PGE [11,12]. To improve
our knowledge on the regulation of M-CSF synthesis
by human bone marrow stromal cells, we have as-
sessed the e¡ects of PGE2 and other lipid mediators
(i.e., 12-hydroxyeicosatetraenoic acid (12-HETE), 15-
HETE, leukotriene B4 (LTB4), LTC4, and lipoxin A4
(LXA4)) on their constitutive and tumour necrosis
factor-K (TNF-K)-induced secretion of M-CSF and
the contribution of cAMP and speci¢c EP receptors
in regulating M-CSF synthesis.
2. Materials and methods
2.1. Reagents
AA, PGE2, LTB4, LTC4, LXA4, 12-HETE and
15-HETE were from Tebu (Le Perray en Yvelines,
France). 11-Deoxy PGE1, 1-OH PGE1, 19-OH PGE2
and sulprostone were from Cayman Chemical (Ann
Arbor, MI, USA). Stock solutions, prepared at the
concentration of 1 mM in ethanol, were stored at
380‡C and diluted in 2% human serum albumin
(HSA) to the appropriate concentration immediately
before use. Cholera toxin and forskolin (dissolved in
DMSO) were from Sigma (Saint Quentin Fallavier,
France). TNF-K was from Tebu and M-CSF was
from Cetus Corp. (Emeryville, CA, USA).
2.2. Human bone marrow stromal cell cultures
Bone marrow samples were collected by aspiration
from untreated patients referred to the laboratory for
a diagnostic procedure needing a myelogram accord-
ing to the Helsinki recommendations. All samples
used in this study exhibited a normal myelogram.
Mononuclear cells were separated on a Ficoll gra-
dient (400Ug, 20 min), washed two times with
Hank’s balanced salts solution (400Ug, 10 min),
and seeded in culture £asks in RPMI 1640 with
20% FCS, penicillin (100 U/ml) and streptomycin
(100 Wg/ml) at 37‡C in 5% CO2 in air [13]. Adherent
cells were grown to con£uence for 5 to 8 weeks with
weekly changes of medium and were subcultured
after trypsin treatment. In these experimental condi-
tions, more than 99.8% of cells were CD23 and
CD223, indicating the absence of T- and B-cells on
the layers, and 4% of cells were CD14 and CD33,
indicating a monocytic lineage [14].
2.3. Cell stimulation
Bone marrow stromal cells were used at their ¢rst
passage. In a ¢rst set of experiments, cells (2U105
per well) were plated for 24 h in 24-well plates in
2 ml of RPMI 1640 with 20% FCS. Adherent cells
were washed and 2 ml of serum-free medium was
added to each well for 2 days. After washing, 1 ml
of fresh RPMI 1640 was added and cells were stimu-
lated with AA, PGE2, LTB4, LTC4, LXA4, 12-
HETE, 15-HETE, TNF-K or the appropriate vehicle.
Culture supernatants were collected at day 1, 3 and
7, and were stored at 380‡C until M-CSF assay. In a
second set of experiments, cells (2U105 per well)
were stimulated in serum-free medium with various
concentrations of TNF-K (0.1 ng to 100 ng/ml). Me-
dia were then collected at day 1 and stored at 380‡C
until M-CSF assay. In a third set of experiments,
cells (2U105 per well) were stimulated in serum-free
medium with TNF-K (50 ng/ml) in the presence or
absence of AA, PGE2, LTB4, LTC4, LXA4, 12-
HETE, 15-HETE, 11-deoxy PGE1, 1-OH PGE1,
19-OH PGE2, sulprostone, forskolin and cholera
toxin. Media were collected on days 1 and 3 and
stored at 380‡C until M-CSF assay.
2.4. Measurements of M-CSF and cAMP levels
M-CSF levels were measured with an enzyme-
linked immunosorbent assay (ELISA) using the
same rabbit polyclonal antibodies for the M-CSF
capture and signal generation [15]. The sensitivity
of the assay enables detection of M-CSF levels as
low as 6 international units per ml (IU/ml) (Interna-
tional standard at 6U104 IU/ml, NIBSC, Potters
Bar, UK). Intracellular cAMP measurement was per-
formed with an ELISA kit (Cayman Chemical).
Brie£y, human bone marrow stromal cells (2U105)
in 24-well plates were washed and treated with PGE2
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(1 WM or 10 nM), TNF-K (50 ng/ml), LTB4, LXA4,
12-HETE, 15-HETE (all at 1 WM) or the vehicle for
5 min in 0.2 ml of serum-free RPMI 1640. After
addition of 2 volumes of ethanol, cells were scraped
and centrifuged to remove debris. Ethanolic super-
natants were evaporated to dryness and the cAMP
ELISA was done following the manufacturer’s pro-
tocol.
2.5. E¡ect of PGE2 on human bone marrow stromal
cell proliferation
This was assessed by [3H]thymidine incorporation
into DNA and cell counts as previously reported
[16,17]. Brie£y, cells (1U104 per well) were plated
for 24 h in 96-well plates in 100 Wl of RPMI 1640
with 20% FCS. Adherent cells were washed with
HBSS and 200 Wl of serum-free medium was added
to each well for 2 days. Adherent cells (in sextuple
wells) were reactivated with 100 Wl of RPMI 1640
with 5% or 20% FCS. PGE2 or the appropriate ve-
hicle (10 Wl of 2% HSA) were added immediately
after reactivation. After 60 h of incubation, cultures
were pulsed for 12 h with 1 WCi/ml [3H]thymidine
(Amersham, Les Ulis, France) and the cells were
harvested using a Skatron cell harvester.
2.6. M-CSF degradation by human bone marrow
stromal cells
Cells (1U104 per well) were plated for 24 h in
96-well plates in 100 Wl of RPMI 1640 with 20%
FCS. Adherent cells were washed and 200 Wl of se-
rum-free medium was added to each well for 2 days.
After washing, cells were grown in 200 Wl of serum-
free RPMI 1640 in the presence of 5000 UI/ml of M-
CSF (Cetus Corp.) with or without PGE2 (1 WM).
Cell supernatants were recovered after 4, 24, 36 and
72 h and were stored at 380‡C until M-CSF meas-
urements.
2.7. Propidium iodide staining
The onset of apoptosis among human bone mar-
row stromal cells stimulated with 1 WM of PGE2 was
analysed using propidium iodide staining. Cells
(3U105 per well) were plated in duplicate for 24 h
in 6-well plates in 5 ml of RPMI 1640 with 20% FCS.
After washing, 2 ml of RPMI 1640 was added to
each well for 2 days. After washing, 2 ml of RPMI
1640 was added with or without PGE2. In another
experimental procedure, cells were stimulated with
TNF-K (50 ng/ml) in the presence or absence of
PGE2. After 24 h cells were recovered, ¢xed, stained
with propidium iodide and analysed for cell status as
previously described [18,19], cells containing hypodi-
ploid DNA being assumed to be apoptotic [18]. For
these experiments cells were analysed using an XL.2
£ow cytometer (Coulter, Miami, FL, USA).
2.8. Statistical analysis
Results are expressed as mean þ S.E.M. of 3^5 in-
dependent experiments. Comparison between control
groups and treated groups was made using Mann^
Whitney U-test. A P value of less than 0.05 was
considered to be signi¢cant.
3. Results
3.1. E¡ects of PGE2 on the constitutive M-CSF
secretion by human bone marrow stromal cells
Human bone marrow stromal cells cultured in se-
rum-free medium secrete the M-CSF protein in their
culture supernatants (Fig. 1). PGE2 (1 WM) signi¢-
cantly (P6 0.05, four independent experiments) re-
duces this constitutive M-CSF production after
3 and 7 days of culture (Fig. 1). As reported in
Fig. 2, PGE2-treated cells did not metabolize M-
CSF di¡erently than control cells, suggesting that
PGE2 acts on the M-CSF production rather than
on its degradation. In contrast to PGE2, similar
amounts of other lipid molecules (i.e., AA, LTB4,
LTC4, LXA4, 12-HETE and 15-HETE) have no ef-
fect on the M-CSF synthesis by human bone marrow
stromal cells (data not shown). Addition of the cy-
clooxygenase inhibitor indomethacin (1 WM) has no
e¡ect (Ps 0.4, three independent experiments) on the
constitutive M-CSF production by cells cultured for
3 days (30.0 þ 8.7 IU/ml vs. 25.3 þ 7.6 IU/ml for
treated cells and control cells, respectively) or 7 days
(88.3 þ 26.1 IU/ml vs. 87.3 þ 35.3 IU/ml).
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3.2. E¡ect of PGE2 on the TNF-K-induced M-CSF
synthesis by human bone marrow stromal cells
We next assessed the e¡ects of PGE2 in context of
TNF-K stimulation. TNF-K stimulates in a dose- and
time-dependent manner (Fig. 3A and B, respectively)
M-CSF secretion by human bone marrow stromal
cells with 50 ng/ml as suboptimal TNF-K concentra-
tion. PGE2 signi¢cantly reduces the TNF-K-induced
M-CSF synthesis by cells cultured for 1 or 3 days,
respectively (Fig. 4). In these experimental conditions
micromolar amounts of AA, LTB4, LTC4, LXA4,
12-HETE and 15-HETE have no e¡ect (data not
shown). The inhibitory e¡ect of PGE2 is dose-de-
pendent (Fig. 4). Inhibition is obtained when PGE2
is added at the beginning of TNF-K stimulation
whereas addition at 24 or 48 h results in no inhib-
ition of the M-CSF secretion (data not shown). Ad-
dition of indomethacin (1 WM) has no e¡ect (Ps 0.4,
three independent experiments) on the TNF-K-in-
duced M-CSF production by cells cultured for 1 day
(71.3 þ 21.4 IU/ml vs. 72.6 þ 15.3 IU/ml for treated
cells and control cells, respectively) or 3 days
(167.0 þ 26.9 IU/ml vs. 168.0 þ 30.0 IU/ml).
3.3. E¡ect of EP agonists on the TNF-K-induced
M-CSF synthesis by human bone marrow stromal
cells
These experiments were made to ensure which EP
receptor(s) mediated the e¡ect of PGE2 on the
M-CSF synthesis by bone marrow stromal cells.
EP2/EP4 selective agonists (11-deoxy PGE1 and
Fig. 2. E¡ect of PGE2 on the metabolism of exogenous M-CSF
by human bone marrow stromal cells. M-CSF (5000 U/ml) was
added to cells (1U104) cultured in 200 Wl of serum-free medium
in the presence or absence of 1 WM of PGE2. The presence of
M-CSF was then assessed in culture supernatants after various
periods of time. Results are reported as the percentage of
M-CSF recovered in the medium as compared to control values
(mean þ S.E.M. of three independent experiments).
Fig. 1. E¡ect of PGE2 on the spontaneous M-CSF secretion by
human bone marrow stromal cells. Cells (2U105) were stimu-
lated with PGE2 (1 WM) at the beginning of the culture. M-
CSF concentrations were assessed in culture supernatants at
days 1, 3 and 7. Mean þ S.E.M. of four independent experi-
ments. *P6 0.05 as compared to controls (Mann^Whitney
U-test).
Table 1
E¡ect of various EP receptor agonists on the TNF-K-induced M-CSF secretion by human bone marrow stromal cells
Receptor agonist Relative speci¢city Controls TNF-K TNF-K+agonist
11-Deoxy PGE1 EP2/EP4sEP3sEP1 27.0 þ 4.2 63.5 þ 11.4 23.5 þ 2.0*
1-OH PGE1 EP2/EP4 21.0 þ 3.3 51.0 þ 4.0 23.5 þ 2.5*
19-OH PGE2 EP2 22.0 þ 3.4 50.6 þ 4.0 25.3 þ 1.7*
Sulprostone EP3sEP1EEP2/EP4 26.5 þ 4 1 65.0 þ 10.6 54.0 þ 6.4
Cells (2U105) were stimulated with TNF-K (50 ng/ml) in the presence of EP receptor agonists (1 WM). M-CSF levels were assessed at
day 1. Results are reported in IU/ml. Mean þ S.E.M. of four independent experiments.
*P6 0.05 as compared to TNF-K-stimulated cells (Mann^Whitney U-test).
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1-OH PGE1) and EP2 agonist (19-OH PGE2) but not
the EP3/EP1 agonist sulprostone inhibit their TNF-
K-induced M-CSF synthesis at day 1 (Table 1) and
day 3 (data not shown).
3.4. Evidence for cAMP as the mediator of
PGE2-induced inhibition of M-CSF production
Studies have reported the role of cAMP as the
agent of the immunosuppressive e¡ect of PGE2
when acting through EP2/EP4 subtypes [12]. We
have thus investigated if PGE2 stimulates the pro-
duction of cAMP in human bone marrow stromal
cells. PGE2 (1 WM or 10 nM) treatment results in a
signi¢cant (P6 0.05, Mann^Whitney U-test, four in-
dependent experiments) increase in cAMP produc-
tion over a period of 5 min (Table 2). In contrast,
stimulation with TNF-K (50 ng/ml), 12-HETE
(1 WM), 15-HETE (1 WM), LTB4 (1 WM) and
LXA4 (1 WM) has no e¡ect on the level of cAMP
in human bone marrow stromal cells as compared to
controls (Table 2).
We have next assessed if molecules that increase
intracellular cAMP levels can mimic the action of
PGE2 on the M-CSF secretion. Thus, forskolin
(10 WM) and cholera toxin (1 WM) reduce signi¢-
Fig. 4. E¡ect of PGE2 on TNF-K-induced M-CSF secretion by
human bone marrow stromal cells. Cells were stimulated for
1 or 3 days with TNF-K (50 ng/ml) in the presence or absence
of various concentrations of PGE2 added at the time of TNF-
K-stimulation. Mean þ S.E.M. of four independent experiments.
*P6 0.05 as compared to controls (Mann^Whitney U-test).
Fig. 3. Dose-dependent (A) and time-dependent (B) e¡ect of
TNF-K on M-CSF secretion by human bone marrow stromal
cells. (A) Cells were stimulated for 1 day with various concen-
trations of TNF-K. Mean þ S.E.M. of four independent experi-
ments. *P6 0.05 as compared to controls (Mann^Whitney
U-test). (B) Cells were stimulated for 1, 3 and 7 days with
TNF-K (50 ng/ml). Mean þ S.E.M. of four independent experi-
ments. *P6 0.05 as compared to controls (Mann^Whitney
U-test).
Table 2
E¡ect of various molecules on the intracellular levels of cAMP
in human bone marrow stromal cells
Control cells Treated cells
PGE2 (1 WM) 1.0 þ 0.2 79.8 þ 16.4*
PGE2 (10 nM) 1.6 þ 0.4 6.0 þ 1.7*
12-HETE (1 WM) 1.8 þ 0.5 2.8 þ 0.3
15-HETE (1 WM) 1.0 þ 0.1 1.0 þ 0.2
LTB4 (1 WM) 1.3 þ 0.3 1.4 þ 0.4
LXA4 (1 WM) 1.3 þ 0.3 1.6 þ 0.4
TNF-K (50 ng/ml) 1.9 þ 0.4 1.7 þ 0.1
Cells (2U105) were stimulated for 5 min. After ethanolic extrac-
tion cAMP levels were assessed by ELISA. Data (in pmol/
2U105 cells) are reported as mean þ S.E.M. of four independent
experiments using cells from 11 di¡erent donors.
*P6 0.05 as compared to control cells (Mann^Whitney U-test).
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cantly (P6 0.05, three experiments) the TNF-K-in-
duced M-CSF synthesis by bone marrow stromal
cells at day 1 (13.3 þ 1.7 IU/ml, 42.0 þ 10.0 IU/ml
and 65.3 þ 10.3 IU/ml for cholera toxin-treated cells,
forskolin-treated cells and control cells, respec-
tively).
3.5. E¡ect of PGE2 on human bone marrow stromal
cell growth
Previous experiments reported that FCS increased
in a dose-dependent manner [3H]thymidine incorpo-
ration by human bone marrow stromal cells with 5%
and 20% FCS as suboptimal and optimal FCS con-
centrations, respectively [5]. As reported in Table 3,
the addition of PGE2 (1 WM to 100 pM) has no
signi¢cant (Ps 0.2, Mann^Whitney U-test, six inde-
pendent experiments) e¡ect on the [3H]thymidine in-
corporation by cells cultured in 5% or 20% FCS.
3.6. E¡ect of PGE2 on apoptosis of human bone
marrow stromal cells
When apoptosis is examined in our cultures, no
di¡erence is found between cells cultured for 24 h
in serum-free medium with or without 1 WM of
PGE2 (Fig. 5). Similarly, 24 h of stimulation with
TNF-K (50 ng/ml) has no e¡ect on the percentage
of cells containing hypodiploid DNA, and the co-
addition of PGE2 and TNF-K is also devoid of an
apoptotic e¡ect (data not shown).
4. Discussion
In this study we have assessed the role of several
lipid mediators on the regulation of M-CSF synthesis
by human bone marrow stromal cells. We found that
they secrete M-CSF in serum-free medium and en-
hance their M-CSF secretion in a time- and dose-
dependent manner in response to TNF-K. AA me-
tabolites such as LTB4, LTC4, 12-HETE, 15-HETE
and LXA4 have no e¡ect on the M-CSF secretion by
human bone marrow stromal cells while several of
them modulate their IL-6, IL-8 and leukaemia inhib-
itory factor (LIF) synthesis [20,21]. In contrast, the
Fig. 5. Analysis of apoptosis in human bone marrow stromal
cells stimulated with PGE2. Cells were cultured in serum-free
medium for 24 h in the absence (A) or presence (B) of 1 WM of
PGE2. After propidium iodide staining, cells were analysed on
a XL.2 £ow cytometer for DNA content. Data were analysed
using XL.2 Software to assess the percentage of cells with a hy-
podiploid content of DNA (i.e., apoptotic cells). Panels A and
B depict typical DNA histograms showing the DNA content of
bone marrow stromal cells. 1, hypodiploid cells (less than 5%
of cells) ; 2, G0/G1 cells ; 3, G2/M cells.
Table 3
E¡ect of PGE2 on the [3H]thymidine incorporation of human bone marrow stromal cells
CS Controls 1 WM 100 nM 10 nM 1 nM 100 pM
5% 2048 þ 604 1613 þ 452 2453 þ 955 2201 þ 746 2123 þ 771 1718 þ 448
20% 7774 þ 2860 4465 þ 1769 6762 þ 2309 7383 þ 2677 8061 þ 3111 7435 þ 2685
Cells were grown with 5% or 20% of FCS in medium. Data (in dpm) are the mean þ S.E.M. of six independent experiments in sextu-
ple. Data for PGE2-treated cells were not signi¢cantly (Ps 0.2, Mann^Whitney U-test) di¡erent as compared to controls.
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present study clearly shows that PGE2 is a potent
inhibitor of the constitutive and TNF-K-induced
M-CSF secretion by human bone marrow stromal
cells. Previous studies have shown that PGE2 de-
creases CSF synthesis in several cell types. Thus,
PGE2 reduces M-CSF production by human mono-
cytes [9] and granulocyte macrophage-CSF (GM-
CSF) secretion by human synovial [10] and marrow
¢broblasts [22]. The inhibition of TNF-K-induced M-
CSF synthesis is dependent of the time of PGE2 ad-
dition. Inhibition occurs only when PGE2 is added at
the time of TNF-K-stimulation. This indicates that
PGE2 cannot regulate M-CSF synthesis by fully ac-
tivated bone marrow stromal cells. The inhibitory
e¡ect of PGE2 is not due to a non-speci¢c e¡ect since
the inhibition is found only when PGE2 is added at
the beginning of the culture and since similar con-
centrations of other AA metabolites have no e¡ect.
The reduced M-CSF synthesis is not due to a de-
creased cell number since PGE2 has no signi¢cant
e¡ect on the cell proliferation (assessed by
[3H]thymidine incorporation) and since PGE2-treated
cell did not exhibit an elevated apoptotic process
(assessed by propidium iodide staining). Finally, pre-
vious experiments have reported that in similar ex-
perimental conditions (i.e., serum-free medium)
PGE2 has no e¡ect on the constitutive or cytokine-
induced secretion of LIF and IL-6 by human bone
marrow stromal cells [20] while it reduces their cyto-
kine-induced IL-8 production without a¡ecting their
constitutive IL-8 secretion [21]. Taken together, these
results suggest that the e¡ect of PGE2 on M-CSF
secretion is speci¢c and not the result of a general
down-regulation of cell activity.
In vivo, circulating levels of M-CSF are regulated
by monocytes/macrophages which bind and degrade
M-CSF after receptor-mediated endocytosis [23]. In
this study, PGE2 has no e¡ect on the weak metabo-
lism of exogenous M-CSF by human bone marrow
stromal cells (i.e., ¢broblast-like cells). This result is
in accord with the absence of M-CSF receptors on
¢broblasts of various origins [24] and suggests that
PGE2 acts on the M-CSF production by human
bone marrow stromal cells rather than on its degra-
dation.
EP2/EP4 agonists reduce the M-CSF secretion by
TNF-K-stimulated bone marrow stromal cells, sug-
gesting a role for EP2/EP4 receptor subtypes in me-
diating the PGE2 inhibition. EP2/EP4 receptors are
reported to generate cAMP production via stimula-
tion of adenyl cyclase [12]. Strengthening their in-
volvement during the inhibition of M-CSF synthesis
in response to PGE2, stimulation of human bone
marrow stromal cells with PGE2 induces an increase
in intracellular cAMP levels. Moreover, cAMP ele-
vating agents such as forskolin and cholera toxin
mimic the PGE2-induced inhibition of M-CSF pro-
duction. Taken together, these results suggest that
the inhibition of M-CSF secretion induced by
PGE2 is mediated through cAMP and PGE receptor
EP2/EP4 subtypes, an hypothesis reinforced by our
recent ¢nding of EP2 and EP4 mRNA expression by
cultured human bone marrow stromal cells [25].
Nanomolar concentrations of PGE2 reduces the
M-CSF secretion by human bone marrow stromal
cells. In contrast, indomethacin has no e¡ect, sug-
gesting no role for endogenous PGE2 in the control
of their M-CSF secretion. Nanomolar concentrations
of PGE2 are secreted in the supernatant of short-
term cultures of human bone marrow mononuclear
cells from healthy controls [26], and patients with
lung carcinoma [27] or multiple myeloma [28].
Bone marrow mononuclear phagocytes are the major
source of this PGE2 production [26]. We may thus
speculate that inside the marrow their PGE2 produc-
tion might modulate the M-CSF secretion by bone
marrow stromal cells.
M-CSF is a haematopoietic growth factor speci¢c
of cells of the mononuclear-phagocytic lineage, and
bone marrow stromal cells play a key regulatory role
during marrow haematopoiesis. Thus, the inhibitory
e¡ect of PGE2 on the M-CSF secretion by human
bone marrow stromal cells might explain why PGE2
is a potent inhibitor of the growth of human bone
marrow colony-forming cells committed to mono-
cytic di¡erentiation but not to those which give rise
to neutrophils and eosinophils [29,30].
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